Table 3.
Adverse events of combination treatment of regorafenib and anti-PD-1 antibodies.
| Adverse event | Patients (n = 23) | ||
|---|---|---|---|
| Any grade | Grades 1-2 | Grade ≥3 | |
| Palmar-plantar Erythrodysesthesia | 9 (39.1) | 7 (30.4) | 2 (8.7) |
| Hypertension | 6 (26.1) | 6 (26.1) | 0 |
| Fatigue | 10 (43.4) | 10(43.4) | 0 |
| Rash | 1 (4.3) | 0 | 1 (4.3) |
| Fever | 0 | 0 | 0 |
| Proteinuria | 1 (4.3) | 1 (4.3) | 0 |
| Liver dysfunction | 5 (21.7) | 4 (17.4) | 1 (4.3) |
| Oral mucositis | 0 | 0 | 0 |
| Diarrhea | 0 | 0 | 0 |
| Decreased appetite | 4 (17.4) | 4 (17.4) | 0 |
| Hyperthyroidism | 0 | 0 | 0 |
| Hypothyroidism | 1 (4.3) | 1 (4.3) | 0 |
| Hoarseness | 1 (4.3) | 0 | 1 (4.3) |
| Platelet count decreased | 2 (8.7) | 2 (8.7) | 0 |
| Lipase elevate | 1 (4.3) | 1 (4.3) | 0 |
| Myocardial enzyme elevation | 1 (4.3) | 1 (4.3) | 0 |
| ALL | 15 (65.2) | 13(56.5) | 5 (21.7) |
Data presented as No. (%).